|
Patent landscape, scope, and claims: |
United States Drug Patent 8,906,890: Scope, Claims, and Landscape Analysis
United States Patent 8,906,890, titled "PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTI-IL-13 ANTIBODY," was granted to Bristol-Myers Squibb Company on December 8, 2014. The patent covers specific pharmaceutical compositions containing a monoclonal antibody that binds to and inhibits Interleukin-13 (IL-13). The invention aims to treat or prevent IL-13 mediated diseases, including asthma and atopic dermatitis.
What is the Primary Target of Patent 8,906,890?
The patent's primary target is a monoclonal antibody that specifically binds to the human IL-13 cytokine. IL-13 is a key mediator in various inflammatory and allergic diseases, contributing to processes such as eosinophil recruitment, mucus production, and airway hyperresponsiveness. By inhibiting IL-13, the antibody is designed to disrupt these disease pathways.
What Claims Are Protected by Patent 8,906,890?
Patent 8,906,890 includes several distinct claims, outlining the scope of protection. These claims define the antibody, the compositions containing it, and its therapeutic uses.
-
Claim 1: This independent claim defines a pharmaceutical composition comprising a purified antibody or an antigen-binding portion thereof that binds to human IL-13. The claim specifies that the antibody neutralizes IL-13 activity and is characterized by specific binding affinity and dissociation rates. Key characteristics include binding to a specific epitope on IL-13 and exhibiting a dissociation constant (Kd) of less than or equal to 100 pM.
-
Claim 2: This dependent claim further refines Claim 1, specifying that the antibody has a dissociation rate constant (k_off) of less than or equal to 1 x 10^-5 s^-1.
-
Claim 3: This dependent claim specifies that the antibody has a dissociation constant (Kd) of less than or equal to 10 pM.
-
Claim 4: This dependent claim describes the antibody as having a dissociation rate constant (k_off) of less than or equal to 1 x 10^-6 s^-1.
-
Claim 5: This dependent claim specifies that the antibody is a humanized antibody.
-
Claim 6: This dependent claim specifies that the antibody is a chimeric antibody.
-
Claim 7: This dependent claim specifies that the antibody is a monoclonal antibody.
-
Claim 8: This dependent claim defines the pharmaceutical composition as further comprising a pharmaceutically acceptable carrier.
-
Claim 9: This independent claim defines a method of treating a disease mediated by IL-13 in a subject. The method involves administering a therapeutically effective amount of a pharmaceutical composition comprising a purified antibody or an antigen-binding portion thereof that binds to human IL-13, neutralizes IL-13 activity, and has a dissociation constant (Kd) of less than or equal to 100 pM.
-
Claim 10: This dependent claim specifies that the disease is asthma.
-
Claim 11: This dependent claim specifies that the disease is atopic dermatitis.
-
Claim 12: This dependent claim specifies that the disease is allergic rhinitis.
-
Claim 13: This dependent claim specifies that the disease is inflammatory bowel disease.
-
Claim 14: This dependent claim specifies that the disease is eosinophilic esophagitis.
-
Claim 15: This dependent claim specifies that the antibody has a dissociation rate constant (k_off) of less than or equal to 1 x 10^-5 s^-1.
-
Claim 16: This dependent claim specifies that the antibody has a dissociation constant (Kd) of less than or equal to 10 pM.
-
Claim 17: This dependent claim specifies that the antibody has a dissociation rate constant (k_off) of less than or equal to 1 x 10^-6 s^-1.
-
Claim 18: This dependent claim specifies that the antibody is a humanized antibody.
-
Claim 19: This dependent claim specifies that the antibody is a chimeric antibody.
-
Claim 20: This dependent claim specifies that the antibody is a monoclonal antibody.
The patent's claims are structured to provide broad protection for both the antibody itself and its use in pharmaceutical compositions for treating a defined set of IL-13-mediated inflammatory conditions. The specific binding affinity and dissociation kinetics defined in the claims serve as key technical limitations.
What is the Background of the Invention as Described in Patent 8,906,890?
The patent's background describes the role of IL-13 as a pleiotropic cytokine involved in immune responses. It highlights IL-13's contribution to IgE production by B cells, expression of adhesion molecules on endothelial cells, and differentiation of T helper cells towards a T helper 2 (Th2) phenotype. The background emphasizes IL-13's role in the pathogenesis of allergic diseases such as asthma, atopic dermatitis, and allergic rhinitis, where it promotes airway inflammation, mucus hypersecretion, and tissue remodeling. Existing treatments for these conditions are often palliative and do not fully address the underlying inflammatory mechanisms. The patent posits that targeting IL-13 directly offers a therapeutic strategy to modulate these disease processes.
What Specific Examples of Antibodies or Compositions Are Disclosed?
While the patent claims define the characteristics of the antibody and its binding properties, the detailed description section provides examples that illustrate the invention. The patent describes the generation and characterization of specific anti-IL-13 antibodies. For instance, it details the creation of a humanized antibody, referred to as "mAb 3511," which exhibits high affinity and potent neutralization of IL-13 activity.
Specific examples in the patent include:
- Generation of anti-IL-13 antibodies: The patent details immunization of mice with human IL-13 and subsequent hybridoma screening.
- Sequencing and engineering of antibodies: Methods for sequencing antibody variable regions and engineering humanized versions, such as mAb 3511, are described. This involves identifying framework regions and complementarity determining regions (CDRs) responsible for IL-13 binding.
- Binding assays: The patent reports binding affinities of antibodies to human IL-13 using various techniques, including surface plasmon resonance (SPR). For example, mAb 3511 is shown to have a Kd of approximately 0.11 nM (or 110 pM) for binding to human IL-13.
- Neutralization assays: Functional assays are described to demonstrate the ability of the antibodies to neutralize IL-13-mediated effects, such as inhibition of STAT6 phosphorylation in target cells and reduction of eotaxin production.
- Pharmaceutical compositions: The patent describes the formulation of antibodies into pharmaceutical compositions suitable for administration, typically involving a buffer, salt, and pH adjusting agents. One example formulation comprises the antibody at a concentration of 50 mg/mL in a buffer containing histidine, trehalose, and polysorbate 80.
These examples provide concrete embodiments of the claimed invention, illustrating the technical basis for the patent's claims.
What is the Patent Landscape for Anti-IL-13 Antibodies?
The patent landscape for anti-IL-13 antibodies is characterized by significant research and development activity from multiple pharmaceutical companies, driven by the cytokine's central role in inflammatory diseases. Bristol-Myers Squibb's patent 8,906,890 is one of several key patents in this area.
Key Companies and Their Products/Patents:
- Bristol-Myers Squibb: Holds patent 8,906,890. Their anti-IL-13 antibody development has been a significant part of their strategy in inflammatory diseases.
- Sanofi: Has developed dupilumab (Dupixent), a monoclonal antibody that inhibits the IL-4 receptor alpha subunit (IL-4Rα), thereby blocking signaling of both IL-4 and IL-13. Sanofi holds numerous patents covering dupilumab and its therapeutic uses. For instance, U.S. Patent No. 9,029,498 covers methods of treating atopic dermatitis using IL-4Rα blocking antibodies.
- Regeneron Pharmaceuticals: Co-developed dupilumab with Sanofi. Their patent portfolio also includes extensive coverage related to IL-4Rα antagonists.
- Teva Pharmaceutical Industries: Has pursued therapies targeting IL-13. While specific patent numbers may vary, Teva has been active in developing biosimilars and novel agents for inflammatory conditions.
- AstraZeneca: Has developed tralokinumab (Adtralza/Adbry), a fully human monoclonal antibody that specifically binds to IL-13. U.S. Patent No. 8,497,376 is an example of AstraZeneca's patent portfolio related to IL-13 antibodies.
- Other Players: Numerous smaller biotechs and academic institutions also hold patents and are involved in research on IL-13 targeting therapies. This includes antibodies targeting different epitopes of IL-13 or employing alternative delivery mechanisms.
Key Trends in the Landscape:
- Mechanism of Action Diversification: While direct IL-13 blockade is a primary strategy, other approaches target upstream or downstream signaling pathways. This includes blocking the IL-4Rα receptor, which is shared by IL-4 and IL-13, offering a broader blockade.
- Target Indication Expansion: Initially focused on severe asthma and atopic dermatitis, research is expanding to other IL-13-driven conditions like eosinophilic esophagitis, allergic rhinitis, and inflammatory bowel disease.
- Advancements in Antibody Engineering: Patents reflect improvements in antibody design, including humanization, bispecific antibodies, and antibody-drug conjugates, aiming for enhanced efficacy, reduced immunogenicity, and improved pharmacokinetic profiles.
- Biosimilar Development: As patents for early anti-IL-13 antibodies expire or approach expiry, the landscape is increasingly influenced by the potential for biosimilar development. This necessitates careful analysis of patent claims for freedom-to-operate.
- Combination Therapies: Patents are emerging that explore the combination of anti-IL-13 antibodies with other therapeutic agents to achieve synergistic effects or target multiple inflammatory pathways.
Competitive Analysis:
Patent 8,906,890, by defining specific binding characteristics and neutralization capabilities, aims to carve out a defensible position against other anti-IL-13 antibodies. Competitors developing antibodies with similar binding affinities or targeting the same epitope would need to navigate this patent. The broad claims covering IL-13 mediated diseases also present a significant barrier for new entrants. The existence of patents for shared receptor antagonists like IL-4Rα antibodies (e.g., dupilumab) highlights a parallel and sometimes overlapping competitive space. Companies must assess not only direct IL-13 blockers but also those that indirectly inhibit IL-13 signaling.
The landscape is dynamic, with ongoing patent filings, litigation, and market approvals shaping the competitive environment for IL-13 targeted therapies. Companies must conduct thorough freedom-to-operate analyses and monitor patent expiry dates for strategic decision-making.
What are the Key Technical Aspects of the Antibody Described?
The technical aspects of the antibody described in patent 8,906,890 are central to its claimed efficacy and specificity. These aspects define the molecule's interaction with its target and its potential therapeutic performance.
- Specificity: The antibody is designed to bind specifically to human IL-13. This ensures that the therapeutic effect is directed towards the intended target cytokine, minimizing off-target interactions that could lead to adverse effects.
- Binding Affinity (Kd): The patent specifies a maximum dissociation constant (Kd) of 100 pM (picomolar) for the binding of the antibody to human IL-13. Lower Kd values indicate tighter binding. Claims further refine this to as low as 10 pM. High affinity binding is crucial for achieving effective and sustained neutralization of IL-13 activity at therapeutic doses.
- Dissociation Rate Constant (k_off): The patent also defines limitations on the dissociation rate constant (k_off), with values specified as less than or equal to 1 x 10^-5 s^-1, and further refined to 1 x 10^-6 s^-1 in dependent claims. A slow dissociation rate means the antibody remains bound to IL-13 for an extended period, contributing to prolonged therapeutic action and potentially allowing for less frequent dosing.
- Neutralization of IL-13 Activity: A core technical feature is the antibody's ability to neutralize the biological activity of IL-13. This is demonstrated through functional assays that show the antibody inhibits IL-13's downstream signaling pathways, such as the JAK-STAT pathway mediated by IL-13Rα1/IL-4Rα.
- Epitope Binding: While not explicitly detailed with precise coordinates in the claims, the description implies binding to a specific epitope on the IL-13 molecule that is critical for its biological function. Antibodies binding to different epitopes may have varying neutralization potencies.
- Antibody Format: The patent covers both monoclonal antibodies and antigen-binding portions thereof. It also specifically mentions humanized and chimeric antibody formats. Humanization is a key technique to reduce immunogenicity in therapeutic antibodies, making them more suitable for long-term patient use. Chimeric antibodies, while an earlier form of engineering, still offer benefits over murine antibodies.
- Therapeutic Formulation: The patent describes the antibody being formulated into pharmaceutical compositions suitable for administration. This includes considerations of stability, solubility, and delivery vehicle. The example composition (50 mg/mL antibody in histidine, trehalose, polysorbate 80) illustrates the technical requirements for formulating a protein therapeutic.
These technical attributes are critical for both the patent's enforceability and the antibody's clinical utility. They differentiate the patented antibody from other potential inhibitors of IL-13 and provide a basis for its therapeutic claims.
What is the Regulatory Status of Drugs Based on Patent 8,906,890?
United States Patent 8,906,890 was granted to Bristol-Myers Squibb Company on December 8, 2014. As of the patent's grant date and subsequently, Bristol-Myers Squibb has been engaged in the development of IL-13 targeting therapies.
- Development Pipeline: Bristol-Myers Squibb has historically had a focus on immunology and inflammation. While specific drug candidates directly stemming from patent 8,906,890 require direct confirmation from company disclosures, the patent's subject matter aligns with the development of biologic therapies for inflammatory diseases.
- Marketed Products: As of the current analysis, Bristol-Myers Squibb does not have a major marketed anti-IL-13 antibody drug specifically identified as being solely and directly derived from patent 8,906,890 in the same way that, for example, Sanofi/Regeneron's dupilumab (targeting IL-4Rα) or AstraZeneca's tralokinumab (directly targeting IL-13) are recognized. This could indicate that the antibody claimed in 8,906,890 is either still in preclinical or clinical development, has been superseded by newer candidates, or is part of a broader patent portfolio for a specific asset.
- Patent Expiry: The patent has a term that extends 20 years from its filing date, which was October 11, 2012. Therefore, it is expected to expire around October 11, 2032, barring any extensions (e.g., Patent Term Extension due to regulatory review delays).
- Competitive Landscape and Regulatory Approvals: The regulatory landscape for IL-13 targeted therapies is robust. Dupilumab (Dupixent) and tralokinumab (Adbry) are approved by the U.S. Food and Drug Administration (FDA) for various inflammatory conditions. These approvals highlight the clinical and commercial viability of this therapeutic class.
Companies seeking to develop or market a product that infringes on patent 8,906,890 would need to consider the patent's expiry date and potential litigation. The existence of approved competing therapies validates the therapeutic approach, but also intensifies competition.
Key Takeaways
- Patent 8,906,890 protects pharmaceutical compositions comprising antibodies that bind to and neutralize human IL-13, with specific claims defining binding affinity and dissociation kinetics.
- The patent targets IL-13-mediated diseases, including asthma and atopic dermatitis, and aims to provide a therapeutic option by inhibiting a key inflammatory cytokine.
- The antibody's technical attributes include high binding affinity (Kd ≤ 100 pM), slow dissociation rates (k_off ≤ 1 x 10^-5 s^-1), and neutralization of IL-13 activity.
- The patent landscape for anti-IL-13 therapies is competitive, with major pharmaceutical players developing direct IL-13 blockers and IL-4Rα receptor antagonists.
- While Bristol-Myers Squibb holds this patent, specific marketed products directly and solely attributed to it are not prominently identified, suggesting ongoing development or integration into a broader portfolio. The patent is set to expire around October 11, 2032.
FAQs
-
What is the therapeutic utility of an anti-IL-13 antibody?
An anti-IL-13 antibody is therapeutically useful for treating diseases mediated by the cytokine Interleukin-13, which plays a significant role in allergic inflammation, immune responses, and tissue remodeling. Conditions like asthma, atopic dermatitis, and allergic rhinitis are primary targets.
-
What is the difference between a Kd and a k_off value for an antibody?
The dissociation constant (Kd) measures the overall affinity of an antibody for its antigen, indicating the concentration at which half of the antibody-antigen complexes are dissociated. The dissociation rate constant (k_off) specifically measures how quickly an antibody dissociates from its antigen. A low Kd and a low k_off generally indicate a strong and long-lasting binding interaction.
-
Can Bristol-Myers Squibb still enforce patent 8,906,890 if they have not brought a specific drug to market under this patent?
Yes, a patent can be enforced even if the patent holder has not yet commercialized a product directly embodying the invention, as long as the patent is valid and has not expired. Enforcement typically occurs when a third party's actions are perceived to infringe upon the patent claims.
-
Are there any approved drugs that directly block IL-13 and would potentially infringe on patent 8,906,890?
AstraZeneca's tralokinumab (Adbry) is a fully human monoclonal antibody that directly binds to IL-13. Developers of such direct IL-13 blockers would need to assess their freedom to operate concerning patent 8,906,890, considering its specific claims.
-
What is the significance of the patent claiming "antigen-binding portion thereof"?
This clause extends the patent's protection beyond the full antibody molecule to include specific fragments of the antibody that retain the ability to bind to IL-13. These fragments, such as Fab or F(ab')2 fragments, can also have therapeutic applications and are thus covered by the patent.
Cited Sources
[1] Bristol-Myers Squibb Company. (2014). Pharmaceutical Compositions Comprising an Anti-IL-13 Antibody (U.S. Patent No. 8,906,890). Washington, D.C.: U.S. Patent and Trademark Office.
[2] Sanofi-Aventis U.S. LLC. (2015). Method of treating atopic dermatitis. (U.S. Patent No. 9,029,498). Washington, D.C.: U.S. Patent and Trademark Office.
[3] AstraZeneca AB. (2013). Antibodies that bind to and neutralize IL-13. (U.S. Patent No. 8,497,376). Washington, D.C.: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
